Explore the vast range of titles available.

The gut microbiota plays a critical role in maintaining gastrointestinal homeostasis, immune regulation, and metabolic processes. Recent evidence has highlighted its significant influence on gastric carcinogenesis. Helicobacter pylori, a well-established class I carcinogen, remains the most prominent microbial risk factor for gastric cancer. However, emerging studies indicate that alterations in the broader gastric and intestinal microbial communities, referred to as dysbiosis, may also contribute to tumor initiation, progression, and immune evasion. These microbial shifts can lead to chronic inflammation, genotoxic metabolite production, and modulation of signaling pathways such as NF-κB and Wnt/β-catenin. This review explores the current understanding of the gut microbiome’s contribution to gastric cancer pathogenesis, including microbial signatures associated with precancerous lesions and the tumor microenvironment. Furthermore, the potential of microbiota-based biomarkers and therapeutic interventions, including probiotics, prebiotics, and fecal microbiota transplantation, is discussed as part of emerging precision medicine strategies.

Background: Liver transplantation has become the standard of care for patients with end-stage liver disease. Despite advances in surgical techniques, immunosuppression, and perioperative care, disparities in access and outcomes persist across demographic and socioeconomic lines. Objective: To assess trends and disparities in liver transplant admissions in the United States from 2016 to 2021, examining demographic patterns, in-hospital mortality, hospital charges, length of stay, and socioeconomic factors. Methods: Using the National Inpatient Sample (NIS) from 2016 to 2021, we identified liver transplant admissions using ICD-10 PCS codes 0FY00Z1 and 0FY00Z2. Demographic characteristics (age, sex, race, insurance status, and income quartile), clinical outcomes, and resource utilization metrics were analyzed. One-way ANOVA and Hensel’s test were used to assess variance and distribution homogeneity, with a significance threshold of p < 0.05. Results: A total of 9677 liver transplant admissions were analyzed. The mean recipient age remained stable (51–52 years), with males comprising ~62% of transplants. White patients constituted the largest group of recipients (~66–68%), followed by Hispanic (~14–17%) and Black patients (~7–10%). The proportion of transplants relative to liver failure admissions remained stable across racial groups, indicating no widening racial gap during the study period. In-hospital mortality post-transplant remained low (2.37–3.52%) and did not differ significantly by race (p = 0.23), sex (p = 0.24), or income quartile (p = 0.13). Similarly, Charlson Comorbidity Index > 5 did not predict inpatient mortality (p = 0.154). Hospital charges ranged from$578,000 to $ 766,000, with an average stay of ~21 days. Conclusions: Liver transplantation outcomes, including in-hospital mortality, appear consistent across demographic and socioeconomic groups once patients are admitted for transplant. However, broader disparities in access persist, necessitating further research into pre-transplant barriers and long-term outcomes. These findings support the need for equitable healthcare strategies aimed at optimizing transplant candidacy and survival across all populations.

AIM: The aim of our study was primarily to analyze hospital outcomes for acute decompensated heart failure (ADHF) admissions with a comorbid diagnosis of chronic liver disease (CLD). METHODS: The NIS was used to select ADHF admissions. The population characteristics of general ADHF admissions were compared with ADHF admissions with a comorbid diagnosis of CLD. Multivariate probit logistic regression was used to analyze the association between a documented diagnosis of CLD/alcoholic liver disease and all-cause mortality in ADHF admissions. Confounders were accounted for. Propensity scoring and nearest neighbor matching were conducted to select a matched cohort with and without CLD from ADHF admissions to further look at mortality outcomes. RESULTS: ADHF admissions with a comorbid diagnosis of CLD had a significantly higher proportion of all-cause mortality, 0.054 (0.053–0.057), a higher length of hospital stay, 6.95 days (6.84–7.06), and a higher mean of total hospital charges, USD 88,068.1, when compared to ADHF admissions without a comorbid diagnosis of CLD: all-cause mortality, 0.045 (0.044–0.046); length of hospital stay, 6.18 days (6.13–6.23); and mean total hospital charges, USD 79,946.21. A comorbid diagnosis of CLD had a significant association with all-cause mortality in ADHF admissions: OR 1.23 (1.17–1.29) after accounting for confounders. In the propensity-matched cohorts, the cohort with a diagnosis of CLD from the ADHF admissions had a higher proportion of all-cause mortality, 0.042 (0.036–0.049), when compared to the cohort without a diagnosis of chronic liver disease, 0.027 (0.022–0.033). CONCLUSIONS: In analyzing the mortality and healthcare utilization outcomes for ADHF admissions, the comorbid diagnosis of CLD is shown to have significantly higher all-cause mortality, higher length of hospital stay, and higher mean total charges when compared to ADHF admissions without a diagnosis of CLD. A documented diagnosis of CLD had a statistically significant association with all-cause mortality in ADHF admissions after accounting for confounding factors.

Background: Appendiceal neuroendocrine tumors (NETs) rank as the third most frequent neoplasm affecting the appendix, originating from enterochromaffin cells. This study aims to evaluate the influence of various prognostic factors on the mortality rates of patients diagnosed with NETs of the appendix. Methods: Conducted retrospectively, the study involved 3346 patients, utilizing data sourced from the Surveillance, Epidemiology, and End Results (SEER) database. Our analysis centered on investigating demographic characteristics, clinical features, overall mortality (OM), and cancer-specific mortality (CSM) among the cohort. Variables showing a p-value < 0.1 in the univariate Cox regression were incorporated into the multivariate Cox regression analysis. A Hazard Ratio (HR) > 1 indicated an unfavorable prognosis. Results: In the multivariate analysis, higher OM and CSM were observed in males, older age groups, tumors with distant metastasis, poorly differentiated tumors, and those who underwent chemotherapy. Non-Hispanic Black individuals showed elevated mortality rates. Conclusion: Delayed diagnosis may contribute to the increased mortality in this community. Improved access to healthcare and treatment is crucial for addressing these disparities. Larger prospective studies are needed to pinpoint the underlying causes of elevated mortality in non-Hispanic Black populations, and randomized controlled trials (RCTs) are warranted to evaluate therapies for advanced-stage appendix NETs.